Citidaron Prescribing Considerations
Citidaron® Prescribing Considerations1
CITIDARON® is indicated for smoking cessation and reduction of nicotine cravings in smokers who are willing to stop smoking. The treatment goal of CITIDARON® is the permanent cessation of the nicotine-containing products use.
Please refer to the full Summary of Product Characteristics before prescribing CITIDARON®
- Hypersensitivity to the active substance of any of excipients
- Unstable angina
- A history of recent myocardial infarction
- Clinically significant arrhythmia
- A history of recent stroke
- Pregnancy or breastfeeding.
- Ischaemic heart disease
- Heart failure
- Hypertension
- Pheochromocytoma
- Atherosclerosis and other peripheral vascular disease
- Gastric and duodenal ulcer
- Gastroesophageal reflux disease
- Hyperthyroidism
- Diabetes
- Schizophrenia
Other Key Safety Considerations
- Depressed mood may be a symptom of nicotine withdrawal. Clinicians should be aware of the possible emergence of serious neuropsychiatric symptoms in patients attempting to quit smoking with and without treatment.
- Patients should be aware that the simultaneous administration of Citidaron and smoking or use of products containing nicotine could lead to aggravated adverse reactions of nicotine.
- Women of childbearing potential must use highly effective contraception while taking Citidaron. It is currently unknown whether Citidaron may reduce the effectiveness of systemically acting hormonal contraceptives, and therefore women using systemically acting hormonal contraceptives should add a second barrier method.
- There is no clinical experience of Citidaron in patients with renal or hepatic impairment, therefore Citidaron is not recommended for use in this patient population.
- Citidaron is not recommended for use in patients <18 years and patients >65 years
References
- CITIDARON® Summary of Product Characteristics, Consilient Health 2025.
Safety Profile
Get an overview of the safety data and tolerability of Citidaron
Taking Citidaron
See the step-by-step course for taking Citidaron
Resources for you
Find additional support and information to help your patients succeed
Adverse events should be reported. Reporting forms and information are available from HPRA Pharmacovigilance on the HPRA website www.hpra.ie. Adverse events should also be reported to Consilient Health at drugsafety@consilienthealth.com or 012057766.
The information on this website is intended for Health Care Professional who practice in the Republic of Ireland only
Sign up to stay informed about upcoming webinars
IE-CH-1737, September 2025